\r\n
\r\n
Graft Engineering:
\r\n
\r\n
Miltenyi Biotec - CliniMACS Technology
\r\n
\r\n
\r\n Hematopoietic stem cell transplantation (HSCT) is a well-founded therapeutic option for the treatment of a variety of hematologic malignancies and a number of non-malignant diseases.\r\n
\r\n
\r\n Different clinical strategies are being evaluated to engineer stem cell grafts for different purposes based on Miltenyi Biotec technologies and clinical grade antibodies for different epitopes.\r\n
\r\n
\r\n Clinical research in graft manipulation include the depletion of T and B cells in order to prevent severe graft-versus-host disease (GvHD) and post-transplant lymphoproliferative diseases (PTLPD) in allogeneic transplantation,\r\n Depletion of autoreactive T and B cells in autologous transplantation for autoimmune diseases and removal of contaminating Tumor cells from a graft in autologous transplantation.\r\n
\r\n\r\n
\r\n
\r\n
\r\n
The CliniMACS® System allows either
\r\n
\r\n
\r\n - the passive depletion of T and B cells by CD34+ or CD133+ cell enrichment, or
\r\n - the direct depletion of T and B cells by combined CD3/CD19 or TCRα/β/CD19 depletion
\r\n - the direct depletion of Naïve cells by CD45RA depletion to have CD45RO memory cells
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n \r\n
\r\n
\r\n
\r\n Immunotherapy is treatment that uses certain parts of a person’s immune system to fight\r\n diseases such as cancer. This can be done in a couple of ways:\r\n
\r\n
\r\n
\r\n
\r\n - Stimulating your own immune system to work harder or smarter to attack cancer cells
\r\n - Giving you immune system components, such as man-made immune system proteins
\r\n
\r\n
\r\n
\r\n Some types of immunotherapy are also sometimes called biologic therapy or biotherapy.\r\n In the last few decades immunotherapy has become an important part of treating some\r\n types of cancer. Newer types of immune treatments are now being studied, and they,ll\r\n impact how we treat cancer in the future.\r\n
\r\n
\r\n Immunotherapy includes treatments that work in different ways. Some boost the body's\r\n immune system in a very general way. Others help train the immune system to attack\r\n cancer cells specifically.\r\n
\r\n
\r\n Immunotherapy works better for some types of cancer than for others. It's used by itself\r\n for some of these cancers, but for others it seems to work better when used with other\r\n types of treatment.\r\n
\r\n
\r\n Immunotherapeutic strategies have evolved using isolated antigen-specific T cells to treat infectious complications after hematopoietic stem cell transplantation (SCT) and SOT as well as malignant diseases.\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n\r\n
\r\n Natural Killer Cells (CD56) : potentially powerful tool for induction of anti-tumor and anti-infectious capacity in the treatment of various malignant diseases. These strategies may be used in combination with the MACS® GMP Product Line for the GMP-compliant manufacturing of cellular products including cultivation and expansion.\r\n
\r\n
\r\n
\r\n Dendritic Stem cells (CD14) : Dendritic cells (DCs) are the most professional antigen-presenting cells and play a central role in eliciting specific adaptive and humoral immune responses. These features make DCs a very attractive tool for immunotherapeutic approaches by stimulating patients to develop their own immunity to cancer.\r\n
\r\n
\r\n
\r\n Tregulatory cells (CD25) : Naturally occurring regulatory T cells (Treg cells) have been shown to play an important role in various immunotherapeutic settings. First in-human trials have been completed and experts agree that Treg cells have demonstrated promising results in the prevention of graft-versus-\r\n host disease (GvHD) and regarding safety in human leukocyte antigen- (HLA) haploidentical stem cell transplantation and umbilical cord blood transplantation, respectively\r\n
\r\n
\r\n
\r\n Mesenchymal cells : In general, mesenchymal stem cells (MSC) have been investigated in a variety of clinical trials for the treatment of graft-versus-host disease and tissue regeneration. The antigen CD271 is expressed on MSC and can be used for the enrichment of these cells. The characterization of CD271+ cells revealed that the colony-forming-unit fibroblast (CFU-F) potential is highly and exclusively enriched in the CD271+ cell fraction after enrichment using the CliniMACS® Plus System. Following this strategy, a well-defined cell population can be used either directly or culture expanded for pre-clinical and clinical investigations.\r\n
\r\n
\r\n
\r\n
\r\n
\r\n 
\r\n
\r\n
\r\n Therapeutic Procedure:\r\n
\r\n - Apheresis
\r\n - Plasma exchange
\r\n - Extracorporeal photopheresis
\r\n - Cellular therapy
\r\n
\r\n
\r\n
\r\n
\r\n
\r\n 
\r\n 
\r\n
\r\n
\n \n